30 August 2023>: Articles
Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report
Challenging differential diagnosis, Unusual setting of medical care, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Wallace Stwart Carvalho Padilha A* , Bruno Nogueira Cesar A , Samara Theodoro Pacheco B , Alessandra Alves De Sousa B , Felipe Lourenço Ledesma C , Denise Maria Avancini Costa Malheiros C , Marcela Crosara Alves Teixeira ADOI: 10.12659/AJCR.940906
Am J Case Rep 2023; 24:e940906
Table 1. Timeline of laboratory examinations and eculizumab infusion.
Examination | Day of hospitalization | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 7 | 8 | 9 | 15 | 17 | 22 | 26 | 29 | 1* | 2** | |
Creatinine (mg/dL) | 1.32 | 2.39 | 3.71 | 4.49 | 4.08 | 3.80 | 4.29 | 3.98 | 3.34 | 2.16 | 1.36 |
LDH (U/L) | 483 | 505 | 519 | 445 | 428 | 393 | 432 | 393 | |||
Haptoglobin (mg/dL) | 7.5 | 30.6 | 51.8 | 97 | |||||||
Schizocytes | 4% | 4% | 3% | 0 | 0 | ||||||
Hemoglobin (g/dL) | 7.6 | 6.9 | 8.1 | 8.0 | 8.3 | 7.2 | 9.3 | 8.7 | 8.3 | 9.2 | 9.9 |
Platelets (10/mm) | 82 | 103 | 104 | 106 | 69 | 45 | 44 | 59 | 93 | 118 | 125 |
Eculizumab | X | X | X | X | |||||||
* One week after discharge. ** Two weeks after discharge. # After hemotransfusion. |